Understand the source comparison
SS-LUP-332 Results Timeline: Outcome Comparison
The table below summarizes expected outcomes across different timeline windows for SS-LUP-332 research applications. Measurement timing determines what you'll observe. Early metabolic markers predict later outcomes but aren't substitutes for them. Days 1–14 AM
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below summarizes expected outcomes across different timeline windows for SS-LUP-332 research applications. Measurement timing determines what you'll observe. Early metabolic markers predict later outcomes but aren't substitutes for them.
- Days 1–14
- AMPK activation, RER shift toward fat oxidation, fasting glucose ↓ 4–8%
- No measurable change
- Measure only if study includes tissue biopsy or advanced metabolic assessment
- Weeks 4–8
- Energy expenditure ↑ 3–7%, mitochondrial biogenesis detectable, substrate preference shift
- Weight ↓ 1–3%, body composition trends only
- Submaximal endurance ↑ 5–10% in some models
- Ideal window for metabolic mechanism validation. Too early for body composition primary endpoints
- Weeks 12–20
- Sustained metabolic elevation, stable insulin sensitivity improvement
- Fat mass ↓ 8–15%, lean mass preserved or ↑ 2–4% depending on caloric state
- Strength outcomes variable, endurance ↑ 10–18%
- Primary window for body composition and functional outcomes. Statistically significant changes emerge here
- Beyond Week 20
- Metabolic effects plateau, no further increase in mitochondrial density
- Continued slow improvement, rate of change decelerates significantly
- Performance gains plateau
- Extended administration shows diminishing marginal returns after week 20–24